SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Madam C. J. Walker

PatientSarah Walker
Date of birth1976-12-23
IdentifiersMRN HR-ET019-SYN; SSN (made up) 000-19-7062
Document date2026-02-23
AuthorHarriet Okonjo-Bell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of the 24-hour ambulatory blood pressure and the repeat kidney tests, with a kidney ultrasound and a nephrology consultation. [S]

History of Present Illness

Madam Walker returns two weeks after her first visit. She wore the ambulatory monitor for 24 hours on a day at home and has taken home readings morning and evening since, including on a three-day trip; the home average is 152/96. Her morning headaches continue on some days. She has taken no ibuprofen or naproxen. Her office sent the results of last year's executive physical: creatinine 1.18 mg/dL and protein 1+ on a urine dipstick, with no albumin test. She had the kidney ultrasound this morning and then met Dr. Achterberg of nephrology here. She has read about kidney disease and asked directly whether she is heading for dialysis, and what it would take to avoid it without giving up her travel. [S]

ElementDetail
Ambulatory monitoring24-hour mean 149/94; daytime 154/98; night 140/88
Home blood pressureAverage 152/96 over seven days, travel days included
Earlier resultsCreatinine 1.18 mg/dL and dipstick protein 1+ about a year ago
Kidney ultrasoundThis morning

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or weight loss
NeurologicalPositiveMorning headaches on some days; no weakness or vision loss
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
GenitourinaryNegativeNo blood in the urine; gets up once at night to pass urine
MusculoskeletalNegativeNo joint pain or rash

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg oral tablet, one tablet each morningOne tablet each morning, at the same home time when travelingOral route2026-02-23 to 2026-03-09completedS
Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet each morning, with sick-day rulesOral route2026-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-02-23Body height163cmS
2026-02-23Body weight78.6kgS
2026-02-23Body mass index (BMI) [Ratio]29.6kg/m2S
2026-02-23Systolic blood pressure160mm[Hg]S
2026-02-23Diastolic blood pressure100mm[Hg]S
2026-02-23Heart rate80/minS
2026-02-23Respiratory rate16/minS
2026-02-23Body temperature36.6CelS
2026-02-23Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-23Albumin/Creatinine [Mass Ratio] in Urine294mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-02-23Creatinine [Mass/volume] in Serum or Plasma1.21mg/dL0.59-1.04 mg/dLHighS
2026-02-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-02-23Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-02-23Phosphate [Mass/volume] in Serum or Plasma3.6mg/dL2.5-4.5 mg/dLNormalS
2026-02-23Parathyrin.intact [Mass/volume] in Serum or Plasma58pg/mL15-65 pg/mLNormalS
2026-02-2325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma31ng/mL30-100 ng/mLNormalS

Physical Exam

Vital signs recorded on 2026-02-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 160/100 (average of two readings), pulse 80; weight 78.6 kg
CardiovascularRegular rhythm; sustained apex beat; no murmur or bruit; no ankle swelling
RespiratoryClear

Problems

ProblemClinical statusVerificationCodeProvenance
Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressureactiveconfirmed I12.9S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis.
Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6%activeconfirmed N18.31S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease.
Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate)activeconfirmed E78.5S — Synthetic laboratory finding.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings)Every visitCompleted today160/100
Examination24-hour ambulatory blood pressure monitoringAt diagnosisCompleted today24-hour mean 149/94, daytime 154/98, night 140/88; non-dipping
Self-managementHome blood pressure readingsTwo readings morning and evening for seven days to confirm and after each change; then twice a week, travel days includedCompleted todaySeven-day average 152/96
ExaminationWeight and BMIEvery visitCompleted today78.6 kg, BMI 29.6
LaboratoryPotassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free)Two to four weeks after starting or increasing losartan or empagliflozin; then every six monthsCompleted todayCreatinine 1.21 mg/dL, eGFR 55 (CKD-EPI 2021, race-free); potassium 4.4 mmol/L two weeks ago; panel booked in two weeks after starting losartan and empagliflozin
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; about three months after a treatment change; then every six months for G3a A2Completed today294 mg/g, confirming 286 at intake
LaboratoryCalcium, phosphate and parathyroid hormoneAt diagnosis of G3a, then every 6 to 12 monthsCompleted todayCalcium 9.4, phosphate 3.6 mg/dL; parathyroid hormone 58 pg/mL
Laboratory25-hydroxyvitamin DAt baselineCompleted today31 ng/mL
LaboratoryUrinalysis with microscopyAt diagnosisUp to dateAt intake: 1+ protein, no blood, bland sediment
ImagingKidney ultrasoundOnce, at the diagnosis of CKDCompleted todayNormal-sized kidneys, mildly increased echogenicity, no obstruction
LaboratoryHemoglobinYearly in CKD G3Up to date12.4 g/dL at intake
SurveyKidney failure risk equation (4-variable), 2- and 5-yearYearly for G3 to G5Completed today5-year risk 1.6%, 2-year risk under 1%
Survey10-year ASCVD risk (Pooled Cohort Equations)YearlyCompleted today7.9%, intermediate; CKD a risk enhancer
LaboratoryLipid panel and ALT4 to 12 weeks after starting a statin, then yearlyUp to dateLDL 174 mg/dL at intake; atorvastatin started today
ExaminationBaseline ECG, TSH and A1cAt the diagnosis of hypertensionUp to dateDone at intake: LVH by voltage; TSH 1.9; A1c 5.4%
ImagingEchocardiogramAt diagnosis of stage 2 hypertension or LVH on ECGOrderedBooked for the next visit
ExaminationFundus examinationYearlyUp to dateAt intake: mild arteriolar narrowing, no hemorrhages
Medication safetyMedicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zonesEvery visitCompleted todayNo NSAIDs; sick-day card given; losartan, empagliflozin and atorvastatin explained, including genital hygiene on empagliflozin
Self-managementSodium and diet counselingEvery visitCompleted todayVideo session with the dietitian booked before her next trip
ReferralNephrology reviewAt diagnosis; then about six months, by video if she prefersCompleted todaySeen by Dr. Achterberg today

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026)

Follow-up: Potassium and creatinine in two weeks with the echocardiogram. Home readings twice a day for a week after starting, then twice a week. Call for dizziness, fainting, vomiting or diarrhea (hold losartan and empagliflozin), or swelling of the lips or tongue. Next scheduled visit 2026-03-09: two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram. [S]